CEFACLOR ANHYDROUS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H14ClN3O4S
Molecular Weight	367.809
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

c1ccc(cc1)[C@]([H])(C(=N[C@]2([H])C(=O)N3C(=C(CS[C@]23[H])Cl)C(=O)O)O)N

InChI

InChIKey=QYIYFLOTGYLRGG-GPCCPHFNSA-N

InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.drugs.com/pro/cefaclor.html
Curator's Comment:: description was created based on several sources, including: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/666290

Cefaclor is a semisynthetic cephalosporin antibiotic for oral administration. As with other cephalosporins, the bactericidal action of Cefaclor results from inhibition of cell-wall synthesis. Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, staphylococci, and Streptococcus pyogenes; Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus pyogenes; Pharyngitis and Tonsillitis, caused by Streptococcus pyogenes; Urinary tract infections, including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci; Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes. Adverse effects considered to be related to therapy with cefaclor are: Hypersensitivity reactions, Rarely, reversible hyperactivity, agitation, nervousness, insomnia, confusion, hypertonia, dizziness, hallucinations, somnolence and diarrhea. Patients receiving Cefaclor may show a false-positive reaction for glucose in the urine with tests that use Benedict's and Fehling's solutions and also with Clinitest® tablets. There have been reports of increased anticoagulant effect when Cefaclor and oral anticoagulants were administered concomitantly.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Canalicular multispecific organic anion transporter 1 19 Target ID: CHEMBL5748 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16434549	Inhibitor 7709	1.15 mM [Ki]
Oligopeptide transporter small intestine isoform 5 Target ID: CHEMBL4605 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16434549	Inhibitor 7709	4.52 mM [Ki]
Solute carrier family 15 member 2 7 Target ID: CHEMBL1743125 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16434549	Inhibitor 7709	65.0 µM [Ki]
Bacterial penicillin-binding protein 226 Target ID: CHEMBL2354204 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1622180 \| https://www.ncbi.nlm.nih.gov/pubmed/6373702 \| https://www.ncbi.nlm.nih.gov/pubmed/21502633 \| https://www.ncbi.nlm.nih.gov/pubmed/20713676	Inhibitor 7709

Conditions

Condition	Modality	Highest Phase	Product
Otitis media 39 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Curative	Approved 8003	CEFACLOR Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date 1.03109761E12
Lower respiratory tract infections 48 Sources: https://www.drugs.com/pro/cefaclor.html	Curative	Approved 8003	CEFACLOR Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date 1.03109761E12
Pharyngitis 28 Sources: https://www.drugs.com/pro/cefaclor.html	Curative	Approved 8003	CEFACLOR Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date 1.03109761E12
Tonsillitis 34 Sources: https://www.drugs.com/pro/cefaclor.html	Curative	Approved 8003	CEFACLOR Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date 1.03109761E12
Urinary tract infections 197 Sources: https://www.drugs.com/pro/cefaclor.html	Curative	Approved 8003	CEFACLOR Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date 1.03109761E12
Skin and skin structure infections 77 Sources: https://www.drugs.com/pro/cefaclor.html	Curative	Approved 8003	CEFACLOR Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date 1.03109761E12

C_max

Value	Dose	Co-administered	Analyte	Population
17.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2393282/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:		CEFACLOR plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
17.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2393282/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:		CEFACLOR plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2393282/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:		CEFACLOR plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: infections Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Other AEs: Hypersensitivity... Other AEs: Hypersensitivity (1.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 200 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 200 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Other AEs: Creatinine serum increased... Other AEs: Creatinine serum increased (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 40 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Other AEs: Aspartate aminotransferase increased, ALT increased... Other AEs: Aspartate aminotransferase increased (1 patient) ALT increased (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Other AEs: Eosinophilia, Pruritus genital... Other AEs: Eosinophilia (1 patient) Pruritus genital (1 patient) Moniliasis (1 patient) Vaginitis (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 500 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 500 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Other AEs: Alkaline phosphatase increased, Blood urea increased... Other AEs: Alkaline phosphatase increased (1 patient) Blood urea increased (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 70 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 70 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Other AEs: Diarrhea... Other AEs: Diarrhea (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
20 mg/kg/day 3 times / day steady, oral Dose: 20 mg/kg/day, 3 times / day Route: oral Route: steady Dose: 20 mg/kg/day, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, pediatric Health Status: unhealthy Condition: infections Age Group: pediatric Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Other AEs: Reaction serum sickness-like... Other AEs: Reaction serum sickness-like (0.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf

AEs

AE	Significance	Dose	Population
Hypersensitivity	1.5%	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: infections Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Creatinine serum increased	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 200 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 200 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
ALT increased	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 40 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Aspartate aminotransferase increased	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 40 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Eosinophilia	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Moniliasis	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Pruritus genital	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Vaginitis	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Alkaline phosphatase increased	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 500 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 500 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Blood urea increased	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 500 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 500 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Diarrhea	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 70 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 70 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Reaction serum sickness-like	0.5%	20 mg/kg/day 3 times / day steady, oral Dose: 20 mg/kg/day, 3 times / day Route: oral Route: steady Dose: 20 mg/kg/day, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, pediatric Health Status: unhealthy Condition: infections Age Group: pediatric Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
PEPT2 9 OAT1 564	PEPT2 32 OAT3 305 OAT1 293 PEPT1 44

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
OAT1 568	inhibitor 3041 Sources: https://pubmed.ncbi.nlm.nih.gov/16434549/	yes [Ki 1150 uM]
PEPT2 11	inhibitor 3041 Sources: https://pubmed.ncbi.nlm.nih.gov/16434549/	yes [Ki 65 uM]

Drug as victim

Target	Modality	Activity
OAT1 293	substrate 3107 Sources: https://pubmed.ncbi.nlm.nih.gov/16434549/	no
PEPT2 32	substrate 3107 Sources: https://pubmed.ncbi.nlm.nih.gov/16434549/	yes [Km 70.2 uM]
OAT3 305	substrate 3107 Sources: https://pubmed.ncbi.nlm.nih.gov/16098483/	yes
PEPT1 44	substrate 3107 Sources: https://pubmed.ncbi.nlm.nih.gov/16434549/	yes

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B2-0069	http://www.3bsc.com/index/pro_info.php?id=19425
3B Scientific (Wuhan) Corp	3B1-01441	http://www.3bsc.com/index/pro_info.php?id=21653
AA Blocks	AA00I9K4	https://www.aablocks.com/goods/Goods/detail?id=AA00I9K4
AEchem Scientific Corp., USA	AE065370	https://www.aechemsc.com/info_products/AE065370.php
AHH Chemical co.,ltd	API-1060	http://www.ahhchemical.com/product/API-1060.html
Aaron Chemicals	AR00IABW	http://www.aaronchem.com/53994-73-3
AbMole Bioscience	M5483	http://www.abmole.com/products/cefaclor.html
Achemtek	0104-018667	http://www.achemtek.com/53994-73-3
Acros Organics	AC455260010	https://www.fishersci.com/shop/products/cefaclor-96-acros-organics-1/AC455260010
Acros Organics	AC455260050	https://www.fishersci.com/shop/products/cefaclor-96-acros-organics/AC455260050
Active Biopharma	ABP000537	http://www.activebiopharma.com/53994-73-3
Ambeed	A580945	https://www.ambeed.com/products/53994-73-3.html
ApexBio Technology	A5559	http://www.apexbt.com/cefaclor.html
Aurora Fine Chemicals LLC	A17.879.960	http://online.aurorafinechemicals.com/info?ID=A17.879.960
BLD Pharm	BD00860299	http://www.bldpharm.com/products/143059-69-2.html
BLD Pharm	BD120238	http://www.bldpharm.com/products/53994-73-3.html
BenchChem	B193732	https://www.benchchem.com/product/b193732
BioCrick	BCC2527	http://www.biocrick.com/Cefaclor-BCC2527.html
BioSynth	C-2461	https://www.biosynth.com/products/biochemistry/culture-media-additives/products/C-2461.html
CSNpharm	CSN10559	https://www.csnpharm.com/products/cefaclor.html
Chem Scene	CS-2134	http://www.chemscene.com/53994-73-3.html
Chemspace	CSSB00016993337	https://chem-space.com/CSSB00016993337
Clearsynth	CS-O-06266	https://www.clearsynth.com/en/CSO06266.html
Glentham Life Sciences	GA0871	http://www.glentham.com/products/product/GA0871/
Huateng Pharma	F100322	http://en.huatengsci.com/product/Cefaclor.html
Lab Network	LN01343473	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01343473
MedChem Express	HY-B0198	https://www.medchemexpress.com/Cefaclor.html
MuseChem	I003978	https://www.musechem.com/product/I003978.html
Parchem	28476	http://www.parchem.com/chemical-supplier-distributor/Cefaclor-018476.aspx
Sigma-Aldrich	72579_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/72579?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	C6895_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/c6895?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S061062	http://www.sinfoobiotech.com/product/1064465
Smolecule	S523055	http://www.smolecule.com/products/s523055
THE BioTek	bt-263286	https://www.thebiotek.com/product/inhibitors/bt-263286
THE BioTek	bt-308691	https://www.thebiotek.com/product/others/bt-308691
abcr GmbH	AB348868	http://www.abcr.com/shop/en/AB348868
eNovation Chemicals	D964471	https://www.enovationchem.com/ProductDetails.asp?ProductID=D964471
iChemical	EBD2197964	http://www.ichemical.com/products/53994-73-3.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed
Recurrent temporal petrositis.	2001 Apr	11276339
Antibiotic susceptibilities among recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis from fifteen countries.	2001 Jan	11245326
The near fatal lick.	2001 Jan	11211712
Drug resistant Haemophilus influenzae from respiratory tract infection in a tertiary care hospital in north India.	2001 Jan-Mar	11370501
Spectrophotometric determination of selected cephalosporins in drug formulations using flow injection analysis.	2001 Jul	11377057
Serum sickness-like reaction to cefaclor.	2001 Jun	11468048
Evaluation of oral antimicrobial agent levels in tooth extraction sites.	2001 Jun	11402275
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.	2001 Nov	11792017
Novel mechanism of hydrolysis of therapeutic beta-lactams by Stenotrophomonas maltophilia L1 metallo-beta-lactamase.	2001 Sep 7	11443136
Levofloxacin: an updated review of its use in the treatment of bacterial infections.	2002	12269858
Antimicrobial susceptibility of Haemophilus influenzae among children in Beijing, China, 1999-2000.	2002	11951998
Comparative target site pharmacokinetics of immediate- and modified-release formulations of cefaclor in humans.	2002 Apr	11936565
Cutaneous and systemic manifestations of drug-induced vasculitis.	2002 Jan	11816242
Comparative study of cefaclor AF vs. cefuroxime axetil in acute exacerbations of chronic bronchitis.	2002 Jan	11782685
Differentiation of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae from other H. influenzae strains by a disc method.	2002 Mar	11957120
The safety of azithromycin in the treatment of adults with community-acquired respiratory tract infections.	2002 Mar	11932140
An evaluation of cefaclor in Pakistani children with pharyngotonsillitis.	2002 Oct	12553673
[Antimicrobial susceptibility of Streptococcus pneumoniae and Haemophilus influenzae isolated in major hospitals in Nagano Prefecture].	2002 Oct	12532636
Mycobacterium bohemicum cervical lymphadenitis.	2002 Oct	12400532
Natural antibiotic susceptibility of Enterobacter amnigenus, Enterobacter cancerogenus, Enterobacter gergoviae and Enterobacter sakazakii strains.	2002 Sep	12427217
Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000.	2002 Sep	12239225
Synthesis and biological activity of tris- and tetrakiscatecholate siderophores based on poly-aza alkanoic acids or alkylbenzoic acids and their conjugates with beta-lactam antibiotics.	2003	12705174
A case of baboon syndrome associated with group a streptococcal infection.	2003 Jan	12598713
Surveillance of antibiotic resistance in clinical isolates of Streptococcus pneumoniae collected in Belgium during winter 2000-2001.	2003 Mar-Apr	12836494
Antibiotic prophylaxis by low-dose cefaclor in children with vesicoureteral reflux.	2003 May	12736811
[Hypersensitivity reactions to beta-lactam antibiotics in childhood].	2003 May-Jun	12783760

Patents

Sample Use Guides

In Vivo Use Guide

The usual adult dosage is 250 mg every 8 hours. For more severe infections (such as pneumonia) or those caused by less susceptible organisms, doses may be doubled.

Route of Administration: Oral

In Vitro Use Guide

Cefaclor inhibits the gram-negative bacteria. At a level of 12.5 ug/ml, 73% of the E. coli, 90% of the Salmonella, 55% of the Shigella, 77% of the Citrobacter, 91% of the Klebsiella, and 75% of the P. mirabilis isolates were inhibited. However, only 18% of the Enterobacter, 3% of the Serratia, 9% of the Proteus morganii, and 16% of the Providencia strains, and less than 10% of the Proteus vulgaris, Proteus rettgeri, and Bacteroides fragilis isolates, were inhibited. All Pseudomonas strains were as resistant to cefaclor as they were to available cephalosporins.

Name

Type

Language

CEFACLOR ANHYDROUS

Common Name

English

CEFACLOR [MI]

Common Name

English

CEFACLOR [INN]

Common Name

English

CEFACLOR [JAN]

Common Name

English

5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(((2R)-2-AMINO-2-PHENYLACETYL)AMINO)-3-CHLORO-8-OXO-, (6R,7R)-

Common Name

English

CEFACLOR [WHO-DD]

Common Name

English

(6R,7R)-7-(((2R)-2-AMINO-2-PHENYLACETYL)AMINO)-3-CHLORO-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID

Systematic Name

English

Classification Tree Code System Code

NDF-RT

N0000175488